Related Experiment Videos
[Prognostic factors in small cell lung cancer]
Elif Torun1, Ali Fidan, Benan Cağlayan
1Department of Chest Diseases, Dr. Lütfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey. dreliftorun@yahoo.com
Tuberkuloz Ve Toraks
|March 12, 2008
Summary
Prognostic factors for small cell lung cancer (SCLC) were analyzed in 40 patients. Stage emerged as a significant prognostic factor, with limited-stage disease showing better survival than extensive-stage SCLC.
Area of Science:
- Oncology
- Pulmonology
- Medical Diagnostics
Context:
- Small cell lung cancer (SCLC) presents unique challenges in determining prognostic factors and treatment outcomes.
- A prospective analysis of 40 SCLC patients was conducted over one year to address these challenges.
Purpose:
- To identify significant prognostic factors and evaluate treatment results in patients with small cell lung cancer.
- To compare laboratory findings and survival rates between limited and extensive SCLC stages.
Summary:
- The study analyzed 40 small cell lung cancer (SCLC) patients, comparing limited and extensive stages. Laboratory markers like LDH, SGOT, and GGT were significantly higher in the extensive stage. Median survival was 10 months for limited stage versus 3 months for extensive stage.
- While univariate analysis indicated several poor prognostic signs (elevated LDH, CA15-3, GGT, SGOT, hypoproteinemia, poor performance status), only stage was a significant prognostic factor in both univariate and multivariate analyses (p=0.045).
Impact:
- This research highlights the critical role of disease stage in predicting outcomes for small cell lung cancer patients.
- Findings can inform clinical decision-making and patient counseling regarding prognosis and treatment strategies for SCLC.
